Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Assessment of selected food intake frequency in patients with type 1 diabetes treated with personal insulin pumps

Krzyżowska S, Matejko B, Kieć-Wilk B, Wilk M, Małecki M, Klupa T.

Rocz Panstw Zakl Hig. 2019;70(3):259-265.

PMID:
31515985
2.

Risk factors of hypoglycaemia in type 1 diabetes individuals during intensive sport exercise-Data from the SPORTGIVECHANCE event.

Hohendorff J, Ucieklak D, Skupien J, Matejko B, Di Giacomo A, Malecki MT, Klupa T.

Int J Clin Pract. 2019 Aug 27:e13411. doi: 10.1111/ijcp.13411. [Epub ahead of print]

PMID:
31456268
3.

Assessment of Safety and Glycemic Control During Football Tournament in Children and Adolescents With Type 1 Diabetes-Results of GoalDiab Study.

Gawrecki A, Araszkiewicz A, Szadkowska A, Biegański G, Konarski J, Domaszewska K, Michalak A, Skowrońska B, Adamska A, Naskręt D, Jarosz-Chobot P, Szypowska A, Klupa T, Zozulińska-Ziółkiewicz D.

Pediatr Exerc Sci. 2019 Jun 27:1-7. doi: 10.1123/pes.2018-0264. [Epub ahead of print]

PMID:
30955442
4.

Utilization of do-it-yourself artificial pancreas systems in the management of patients with type 1 diabetes: a position statement of the Pump School Education Initiative by Diabetes Poland.

Gawrecki A, Klupa T, Araszkiewicz A, Matejko B, Szadkowska A, Wolnik B, Szymańska-Garbacz E, Jarosz-Chobot P, Myśliwiec M, Czupryniak L, Małecki MT, Zozulińska-Ziółkiewicz D.

Pol Arch Intern Med. 2019 Feb 28;129(2):141-142. doi: 10.20452/pamw.4468. Epub 2019 Feb 28. No abstract available.

5.

A decision algorithm to identify patients with high probability of monogenic diabetes due to HNF1A mutations.

Szopa M, Klupa T, Kapusta M, Matejko B, Ucieklak D, Glodzik W, Zapala B, Sani CM, Hohendorff J, Malecki MT, Skupien J.

Endocrine. 2019 Apr;64(1):75-81. doi: 10.1007/s12020-019-01863-7. Epub 2019 Feb 18.

6.

Insulin pump settings and glucose patterns during a 1008-km non-stop bicycle race in a patient with type 1 diabetes mellitus.

Klupa T, Hohendorff J, Benbenek-Klupa T, Matejko B, Malecki MT.

Acta Diabetol. 2019 May;56(5):593-595. doi: 10.1007/s00592-018-1254-4. Epub 2018 Nov 15. No abstract available.

7.

Basal Insulin Dose in Adults with Type 1 Diabetes Mellitus on Insulin Pumps in Real-Life Clinical Practice: A Single-Center Experience.

Matejko B, Kukułka A, Kieć-Wilk B, Stąpór A, Klupa T, Malecki MT.

Adv Med. 2018 Jun 5;2018:1473160. doi: 10.1155/2018/1473160. eCollection 2018.

8.

Characteristics of gut microbiota in adult patients with type 1 and type 2 diabetes based on next‑generation sequencing of the 16S rRNA gene fragment.

Salamon D, Sroka-Oleksiak A, Kapusta P, Szopa M, Mrozińska S, Ludwig-Słomczyńska AH, Wołkow PP, Bulanda M, Klupa T, Małecki MT, Gosiewski T.

Pol Arch Intern Med. 2018 Jun 30;128(6):336-343. doi: 10.20452/pamw.4246. Epub 2018 Apr 15.

9.

Type 1 Diabetes and Combat Sports: Improvement in Glycemic Control With Gained Experience.

Matejko B, Benbenek-Klupa T, Malecki MT, Klupa T.

J Diabetes Sci Technol. 2018 Sep;12(5):1088-1089. doi: 10.1177/1932296818769337. Epub 2018 Apr 5. No abstract available.

10.

Safe Completion of a Trail Running Ultramarathon by Four Men with Type 1 Diabetes.

Gawrecki A, Zozulinska-Ziolkiewicz D, Matejko B, Hohendorff J, Malecki MT, Klupa T.

Diabetes Technol Ther. 2018 Feb;20(2):147-152. doi: 10.1089/dia.2017.0296. Epub 2018 Jan 2.

PMID:
29293025
11.

Europe has to step up its efforts to produce innovative and safe diabetes technology.

Cnop M, Klupa T, Tentolouris N, Novials A, Burcelin R, van Eimeren M.

Diabetologia. 2017 Dec;60(12):2532-2533. doi: 10.1007/s00125-017-4455-4. Epub 2017 Sep 24. No abstract available.

PMID:
28942556
12.

Type 1 Diabetes at High Altitude: Performance of Personal Insulin Pumps and Patient Metabolic Control.

Matejko B, Gawrecki A, Wróbel M, Hohendorff J, Benbenek-Klupa T, Malecki MT, Zozulińska-Ziółkiewicz D, Klupa T.

Diabetes Technol Ther. 2017 Oct;19(10):600-602. doi: 10.1089/dia.2016.0452. Epub 2017 Aug 23.

PMID:
28832184
13.

A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.

Hohendorff J, Szopa M, Skupien J, Kapusta M, Zapala B, Platek T, Mrozinska S, Parpan T, Glodzik W, Ludwig-Galezowska A, Kiec-Wilk B, Klupa T, Malecki MT.

Endocrine. 2017 Aug;57(2):272-279. doi: 10.1007/s12020-017-1341-2. Epub 2017 Jun 7.

14.

Qualitative Parameters of the Colonic Flora in Patients with HNF1A-MODY Are Different from Those Observed in Type 2 Diabetes Mellitus.

Mrozinska S, Radkowski P, Gosiewski T, Szopa M, Bulanda M, Ludwig-Galezowska AH, Morawska I, Sroka-Oleksiak A, Matejko B, Kapusta P, Salamon D, Malecki MT, Wolkow P, Klupa T.

J Diabetes Res. 2016;2016:3876764. Epub 2016 Oct 11.

15.

Diet-Related Knowledge and Physical Activity in a Large Cohort of Insulin-Treated Type 2 Diabetes Patients: PROGENS ARENA Study.

Klupa T, Możdżan M, Kokoszka-Paszkot J, Kubik M, Masierek M, Czerwińska M, Małecki MT.

Int J Endocrinol. 2016;2016:2354956. Epub 2016 Sep 14.

16.

Type 1 diabetes mellitus at very high altitude. The summit of Mount Damāvand (5670 m) safely reached by 18 patients with type 1 diabetes mellitus.

Gawrecki A, Matejko B, Benbenek-Klupa T, Wróbel M, Hohendorff J, Klupa T.

Pol Arch Med Wewn. 2016 Aug 24;126(7-8):576-8. doi: 10.20452/pamw.3521. Epub 2016 Aug 24. No abstract available.

17.

Metformin in type 1 diabetes mellitus? Revisiting treatment dogmas in diabetes.

Klupa T.

Pol Arch Med Wewn. 2016 Aug 25;126(7-8):461-2. doi: 10.20452/pamw.3533. Epub 2016 Aug 25. No abstract available.

18.

Hypoglycemic episodes are associated with inflammatory status in patients with type 1 diabetes mellitus.

Kiec-Wilk B, Matejko B, Razny U, Stankiewicz M, Skupien J, Klupa T, Malecki MT.

Atherosclerosis. 2016 Aug;251:334-338. doi: 10.1016/j.atherosclerosis.2016.05.002. Epub 2016 May 3.

PMID:
27237074
19.

Personal Insulin Pump With Predictive Low Glucose Management Technology at High Altitude.

Matejko B, Benbenek-Klupa T, Malecki MT, Klupa T.

J Diabetes Sci Technol. 2017 Jan;11(1):176-177. doi: 10.1177/1932296816649973. Epub 2016 Jul 10. No abstract available.

20.

Assessment of Newly Proposed Clinical Criteria to Identify HNF1A MODY in Patients with an Initial Diagnosis of Type 1 or Type 2 Diabetes Mellitus.

Grzanka M, Matejko B, Szopa M, Kiec-Wilk B, Malecki MT, Klupa T.

Adv Med. 2016;2016:4243784. doi: 10.1155/2016/4243784. Epub 2016 Jan 28.

21.

A family with the Arg103Pro mutation in the NEUROD1 gene detected by next-generation sequencing - Clinical characteristics of mutation carriers.

Szopa M, Ludwig-Galezowska AH, Radkowski P, Skupien J, Machlowska J, Klupa T, Wolkow P, Borowiec M, Mlynarski W, Malecki MT.

Eur J Med Genet. 2016 Feb;59(2):75-9. doi: 10.1016/j.ejmg.2016.01.002. Epub 2016 Jan 8.

PMID:
26773576
22.

Genetic testing for monogenic diabetes using targeted next-generation sequencing in patients with maturity-onset diabetes of the young.

Szopa M, Ludwig-Gałęzowska A, Radkowski P, Skupień J, Zapała B, Płatek T, Klupa T, Kieć-Wilk B, Borowiec M, Młynarski W, Wołkow P, Małecki MT.

Pol Arch Med Wewn. 2015;125(11):845-51. Epub 2015 Nov 9.

23.

Comparison of Glomerular Filtration Rate Estimation from Serum Creatinine and Cystatin C in HNF1A-MODY and Other Types of Diabetes.

Szopa M, Kapusta M, Matejko B, Klupa T, Koblik T, Kiec-Wilk B, Borowiec M, Malecki MT.

J Diabetes Res. 2015;2015:183094. doi: 10.1155/2015/183094. Epub 2015 Aug 10.

24.

Prevalence of Retinopathy in Adult Patients with GCK-MODY and HNF1A-MODY.

Szopa M, Wolkow J, Matejko B, Skupien J, Klupa T, Wybrańska I, Trznadel-Morawska I, Kiec-Wilk B, Borowiec M, Malecki MT.

Exp Clin Endocrinol Diabetes. 2015 Oct;123(9):524-8. doi: 10.1055/s-0035-1559605. Epub 2015 Aug 4.

PMID:
26240958
25.

Are late-night eating habits and sleep duration associated with glycemic control in adult type 1 diabetes patients treated with insulin pumps?

Matejko B, Kiec-Wilk B, Szopa M, Trznadel Morawska I, Malecki MT, Klupa T.

J Diabetes Investig. 2015 Jul;6(4):460-4. doi: 10.1111/jdi.12320. Epub 2015 Jan 14.

26.

Metabolic control in type 1 diabetes patients practicing combat sports: at least two-year follow-up study.

Benbenek-Klupa T, Matejko B, Klupa T.

Springerplus. 2015 Mar 17;4:133. doi: 10.1186/s40064-015-0919-5. eCollection 2015.

27.

The impact of a pure protein load on the glucose levels in type 1 diabetes patients treated with insulin pumps.

Klupa T, Benbenek-Klupa T, Matejko B, Mrozinska S, Malecki MT.

Int J Endocrinol. 2015;2015:216918. doi: 10.1155/2015/216918. Epub 2015 Feb 12.

28.

Association of retrospective markers of glycemia and the use of continuous glucose monitoring in white adults with type 2 diabetes mellitus--a preliminary report.

Solnica B, Grzanka M, Kapusta M, Nowak N, Skupien J, Slowinska-Solnica K, Matejko B, Klupa T, Malecki MT.

Clin Chem Lab Med. 2015 Jan;53(1):e15-7. doi: 10.1515/cclm-2014-0580. No abstract available.

PMID:
25014524
29.

Factors associated with glycemic control in adult type 1 diabetes patients treated with insulin pump therapy.

Matejko B, Skupien J, Mrozińska S, Grzanka M, Cyganek K, Kiec-Wilk B, Malecki MT, Klupa T.

Endocrine. 2015 Feb;48(1):164-9. doi: 10.1007/s12020-014-0274-2. Epub 2014 May 6.

PMID:
24798448
30.

Bolus calculator settings in well-controlled type 1 diabetes patients (glycated hemoglobin < 7%) treated with insulin pumps.

Matejko B, Grzanka M, Kieć-Wilk B, Małecki MT, Klupa T.

J Diabetes Sci Technol. 2013 May 1;7(3):800-1. No abstract available.

31.

Clinical factors affecting the perception of hypoglycemia in type 1 diabetes patients treated with personal insulin pumps.

Matejko B, Grzanka M, Kieć-Wilk B, Małecki MT, Klupa T.

Ann Agric Environ Med. 2013;20(1):152-4.

32.

Medical care of pregnant women with type 1 diabetes: current guidelines and clinical practice.

Cyganek K, Klupa T, Szopa M, Katra B, Małecki MT.

Pol Arch Med Wewn. 2013;123(1-2):59-65. Epub 2013 Jan 23. Review.

33.

Efficacy and safety of insulin pump treatment in adult T1DM patients--influence of age and social environment.

Grzanka M, Matejko B, Cyganek K, Kozek E, Małecki MT, Klupa T.

Ann Agric Environ Med. 2012;19(3):573-5.

34.

Monogenic models: what have the single gene disorders taught us?

Klupa T, Skupien J, Malecki MT.

Curr Diab Rep. 2012 Dec;12(6):659-66. doi: 10.1007/s11892-012-0325-0. Review.

35.

Sulfonylurea use during entire pregnancy in diabetes because of KCNJ11 mutation: a report of two cases.

Gaal Z, Klupa T, Kantor I, Mlynarski W, Albert L, Tolloczko J, Balogh I, Czajkowski K, Malecki MT.

Diabetes Care. 2012 Jun;35(6):e40. doi: 10.2337/dc12-0163. No abstract available.

36.

The influence of dietary carbohydrate content on glycaemia in patients with glucokinase maturity-onset diabetes of the young.

Klupa T, Solecka I, Nowak N, Szopa M, Kiec-Wilk B, Skupien J, Trybul I, Matejko B, Mlynarski W, Malecki MT.

J Int Med Res. 2011;39(6):2296-301.

PMID:
22289546
37.

Insulin pump therapy is equally effective and safe in elderly and young type 1 diabetes patients.

Matejko B, Cyganek K, Katra B, Galicka-Latala D, Grzanka M, Malecki MT, Klupa T.

Rev Diabet Stud. 2011 Summer;8(2):254-8. doi: 10.1900/RDS.2011.8.254. Epub 2011 Aug 10.

38.

Glycemic control and pregnancy outcomes in women with type 2 diabetes from Poland. The impact of pregnancy planning and a comparison with type 1 diabetes subjects.

Cyganek K, Hebda-Szydlo A, Skupien J, Katra B, Janas I, Borodako A, Kaim I, Klupa T, Reron A, Malecki MT.

Endocrine. 2011 Oct;40(2):243-9. doi: 10.1007/s12020-011-9475-0. Epub 2011 Apr 29.

PMID:
21528433
39.

Corticosteroid treatment of kidney disease in a patient with familial lecithin-cholesterol acyltransferase deficiency.

Miarka P, Idzior-Waluś B, Kuźniewski M, Waluś-Miarka M, Klupa T, Sułowicz W.

Clin Exp Nephrol. 2011 Jun;15(3):424-429. doi: 10.1007/s10157-011-0409-1. Epub 2011 Feb 16.

PMID:
21327698
40.

Permanent neonatal diabetes mellitus--the importance of diabetes differential diagnosis in neonates and infants.

Rubio-Cabezas O, Klupa T, Malecki MT; CEED3 Consortium.

Eur J Clin Invest. 2011 Mar;41(3):323-33. doi: 10.1111/j.1365-2362.2010.02409.x. Epub 2010 Nov 4. Review.

PMID:
21054355
41.

The first case report of sulfonylurea use in a woman with permanent neonatal diabetes mellitus due to KCNJ11 mutation during a high-risk pregnancy.

Klupa T, Kozek E, Nowak N, Cyganek K, Gach A, Milewicz T, Czajkowski K, Tolloczko J, Mlynarski W, Malecki MT.

J Clin Endocrinol Metab. 2010 Aug;95(8):3599-604. doi: 10.1210/jc.2010-0096. Epub 2010 May 13.

PMID:
20466780
42.

Dipeptidyl peptidase-IV inhibitors are efficient adjunct therapy in HNF1A maturity-onset diabetes of the young patients--report of two cases.

Katra B, Klupa T, Skupien J, Szopa M, Nowak N, Borowiec M, Kozek E, Malecki MT.

Diabetes Technol Ther. 2010 Apr;12(4):313-6. doi: 10.1089/dia.2009.0159.

PMID:
20210571
43.

Efficacy and safety of sulfonylurea use in permanent neonatal diabetes due to KCNJ11 gene mutations: 34-month median follow-up.

Klupa T, Skupien J, Mirkiewicz-Sieradzka B, Gach A, Noczynska A, Zubkiewicz-Kucharska A, Szalecki M, Kozek E, Nazim J, Mlynarski W, Malecki MT.

Diabetes Technol Ther. 2010 May;12(5):387-91. doi: 10.1089/dia.2009.0165.

PMID:
20184447
44.

Recessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesis.

Garin I, Edghill EL, Akerman I, Rubio-Cabezas O, Rica I, Locke JM, Maestro MA, Alshaikh A, Bundak R, del Castillo G, Deeb A, Deiss D, Fernandez JM, Godbole K, Hussain K, O'Connell M, Klupa T, Kolouskova S, Mohsin F, Perlman K, Sumnik Z, Rial JM, Ugarte E, Vasanthi T; Neonatal Diabetes International Group, Johnstone K, Flanagan SE, Martínez R, Castaño C, Patch AM, Fernández-Rebollo E, Raile K, Morgan N, Harries LW, Castaño L, Ellard S, Ferrer J, Perez de Nanclares G, Hattersley AT.

Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3105-10. doi: 10.1073/pnas.0910533107. Epub 2010 Jan 28.

45.

Glycemic control and selected pregnancy outcomes in type 1 diabetes women on continuous subcutaneous insulin infusion and multiple daily injections: the significance of pregnancy planning.

Cyganek K, Hebda-Szydlo A, Katra B, Skupien J, Klupa T, Janas I, Kaim I, Sieradzki J, Reron A, Malecki MT.

Diabetes Technol Ther. 2010 Jan;12(1):41-7. doi: 10.1089/dia.2009.0081.

PMID:
20082584
46.

The dual-wave bolus feature in type 1 diabetes adult users of insulin pumps.

Klupa T, Skupien J, Cyganek K, Katra B, Sieradzki J, Malecki MT.

Acta Diabetol. 2011 Mar;48(1):11-4. doi: 10.1007/s00592-009-0173-9. Epub 2010 Jan 9.

PMID:
20063022
47.

[Leptin and soluble leptin receptor in children with type 1 diabetes mellitus].

Szalecki M, Pańkowska E, Wysocka-Mincewicz M, Klupa T, Janas R.

Pediatr Endocrinol Diabetes Metab. 2010;16(4):262-9. Polish.

PMID:
21447267
48.
49.

LMNA gene mutation search in Polish patients: new features of the heterozygous Arg482Gln mutation phenotype.

Klupa T, Szopa M, Skupien J, Wojtyczek K, Cyganek K, Kowalska I, Malecki MT.

Endocrine. 2009 Dec;36(3):518-23. doi: 10.1007/s12020-009-9265-0. Epub 2009 Oct 27.

PMID:
19859838
50.

Diabetic retinopathy in permanent neonatal diabetes due to Kir6.2 gene mutations: the results of a minimum 2-year follow-up after the transfer from insulin to sulphonylurea.

Klupa T, Skupien J, Mirkiewicz-Sieradzka B, Gach A, Noczynska A, Szalecki M, Kozek E, Sieradzki J, Mlynarski W, Malecki MT.

Diabet Med. 2009 Jun;26(6):663-4. doi: 10.1111/j.1464-5491.2009.02711.x. No abstract available.

PMID:
19538247

Supplemental Content

Support Center